IP Verse

Agents For Treating Tumours, Use And Method Thereof - EP2944323

The patent EP2944323 was granted to Dingfu Biotarget on Mar 27, 2019. The application was originally filed on Jan 11, 2013 under application number EP13870762A. The patent is currently recorded with a legal status of "Revoked".

EP2944323

DINGFU BIOTARGET
Application Number
EP13870762A
Filing Date
Jan 11, 2013
Status
Revoked
Jul 24, 2020
Publication Date
Mar 27, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GLAXOSMITHKLINEDec 20, 2019J A KEMP -
MERCK PATENTDec 20, 2019- -
PFIZERDec 20, 2019PFIZER -

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2009089149
OPPOSITIONEP2785375
OPPOSITIONWO2009089149
OPPOSITIONWO2010077634
OPPOSITIONWO2012177624
OPPOSITIONWO2013079174
SEARCHWO2009089149
SEARCHWO2012177624

Non-Patent Literature (NPL) Citations (67) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- APETOH, L. ET AL., "Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy", NAT MED, (2007), vol. 13, pages 1050 - 1059
DESCRIPTION- BURNETTE, B. ET AL., "The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity", CANCER RES.
DESCRIPTION- CHEN ET AL., "TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu", IMMUNITY, (2001), vol. 14, pages 715 - 725
DESCRIPTION- FOURCADE, J. ET AL., "Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients", J EXP MED, vol. 207, pages 2175 - 2186
DESCRIPTION- FREEMAN, G.J.; WHERRY, E.J.; AHMED, R.; SHARPE, A.H., "Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade", J EXP MED, (2006), vol. 203, pages 2223 - 2227
DESCRIPTION- HIRANO, F. ET AL., "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.", CANCER RES, (2005), vol. 65, pages 1089 - 1096, XP002419626
DESCRIPTION- J. IMMUNOL., (2000), vol. 165, pages 5133 - 5142
DESCRIPTION- LEE, Y. ET AL., "Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment", BLOOD, (2009), vol. 114, pages 589 - 595
DESCRIPTION- MERRICK A. ET AL., "Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of native T-cell priming", BR J CANCER., (2005), vol. 92, pages 1450 - 1458
DESCRIPTION- MUMPRECHT, S.; SCHURCH, C.; SCHWALLER, J.; SOLENTHALER, M.; OCHSENBEIN, A.F., "Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression", BLOOD, (2009), vol. 114, pages 1528 - 1536
DESCRIPTION- NAKAMOTO, N. ET AL., "Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-l/CTLA-4 blockade", PLOSPATHOG, (2009), vol. 5, page E1000313
DESCRIPTION- OHUCHIDA K. ET AL., "Radiation to mesenchymel fibroblasts increases invasiveness of pancreatic cancer cells through tumor-mesenchymel interactions", CANCER RES., (2004), vol. 64, pages 3215 - 3222
DESCRIPTION- REITS EA ET AL., "Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy", J. EXP MED., (2006), vol. 203, pages 1259 - 1271
DESCRIPTION- WASSERMAN J. ET AL., "Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors", BULL N YACAD MED., (1989), vol. 65, pages 36 - 44
DESCRIPTION- ASANO, K. ET AL., "CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens", IMMUNITY, vol. 34, doi:doi:10.1016/j.immuni.2010.12.011, pages 85 - 95, XP028183617
DESCRIPTION- BARBER, D.L. ET AL., "Restoring function in exhausted CD8 T cells during chronic viral infection", NATURE, (2006), vol. 439, doi:doi:10.1038/nature04444, pages 682 - 687, XP002419629
DESCRIPTION- DAY, C.L. ET AL., "PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression", NATURE, (2006), vol. 443, doi:doi:10.1038/nature05115, pages 350 - 354, XP002487713
DESCRIPTION- TRAUTMANN, L. ET AL., "Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction", NAT MED, (2006), vol. 12, doi:doi:10.1038/nm1482, pages 1198 - 1202, XP055099009
DESCRIPTION- DONG, H. ET AL., "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion", NAT MED, (2002), vol. 8, doi:doi:10.1038/nm730, pages 793 - 800, XP002397368
DESCRIPTION- CURIEL, T.J., "Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity", NAT MED, (2003), vol. 9, doi:doi:10.1038/nm863, pages 562 - 567, XP002311470
DESCRIPTION- CHEN, L., "Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity", NAT REVLMMUNOL, (2004), vol. 4, doi:doi:10.1038/nri1349, pages 336 - 347, XP055141186
DESCRIPTION- ZOU, W.; CHEN, L., "Inhibitory B7-family molecules in the tumor microenvironment", NAT REV IMMUNOL, (2008), vol. 8, doi:doi:10.1038/nri2326, pages 467 - 477, XP009142446
DESCRIPTION- SAKUISHI, K. ET AL., "Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity", J EXP MED, vol. 207, doi:doi:10.1084/jem.20100643, pages 2187 - 2194, XP055052551
DESCRIPTION- WATSON PA; ELLWOOD-YEN K; KING JC; WONGVIPAT J; LEBEAU MM; SAWYERS CL, "Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line", CANCER RES., (20051215), vol. 65, no. 24, doi:doi:10.1158/0008-5472.CAN-05-3441, pages 11565 - 71, XP055137396
EXAMINATION- CARRIE PRINTZ, "Radiation oncologists work to protect patients'", CANCER, (20120701), pages 3223 - 3225
EXAMINATION- CHARLES J ROSSER ET AL, "Molecular fingerprinting of radiation resistant tumors: Can we apprehend and rehabilitate the suspects?", BIOMED CENTRAL, (20090709), vol. 9, no. 225, pages 1 - 10
EXAMINATION- FRANCESCA DE BACCO ET AL, "Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer", J NATL CANCER INST, (20110404), vol. 103, pages 645 - 661
INTERNATIONAL-SEARCH-REPORT- YURU MENG ET AL., "Radiation-inducible Immunotherapy for Cancer: Senescent Tumor Cells as a Cancer Vaccine", MOLECULAR THERAPY, (201205), vol. 20, no. 5, pages 1046 - 1055, XP055261840
OPPOSITION- "Gamma ray", (20191216), URL: https://en.wikipedia.org/ wiki/Gamma_ray, XP055679079
OPPOSITION- "Gamma ray", Encyclopaedia Britannica, (20191216), URL: https://www.britannica.com/print/article/225048
OPPOSITION- Jennifer C. JONES et al., "Impact of Radiation on Immunotherapy Targets", J Immunother, (20091100), vol. 32, no. 9, pages 971 - 972, XP055668346
OPPOSITION- JOHNSON BRYON, "PD-1/PD-L1 Blockade after Transient Lymphodepletion to Treat Myeloma", 27th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC), (20121027), pages 1 - 20, XP055668325
OPPOSITION- JONES et al., "199. Radiation Upregulates Specific Co-stimulatory and Co-inhibitory Immunotherapy Targets", IJ Radiation Oncology.Biology.Physics, (20090000), vol. 75, no. 3, page S94, XP055668342
OPPOSITION- JONES et al., "Abstracts of the 24th Annual Meeting of the International Society for Biological Therapy of Cancer ([SBTC", Journal for ImmunoTherapy of Cancer, (20090000), vol. 32, no. 9, pages 941 - 1012
OPPOSITION- J. ZENG et al., "90. Combining anti-PD-1 (B7-H1) immunotherapy with stereotactic radiosurgery in a mouse orthotopic glioblastoma model", Radiotherapy and Oncology, (20120000), vol. 102, page S1, S34, XP055668315
OPPOSITION- KEARL et al., "Abstracts for the 27th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC", Journal for Immunotherapy, (20120000), vol. 35, no. 9, pages 721 - 791
OPPOSITION- KEARL et al., "PD-1/PD-L1 Blockade after Transient Lymphodepletion to Treat Myeloma", (20120000), pages 1 - 20, XP055668325
OPPOSITION- KEARL et al., "PD-1 /PD-L1 blockade after transient lymphodepletion to treat myeloma", Journal of Immunotherapy, (20120000), vol. 35, no. 9, pages 721, 730 - 731, XP055668313
OPPOSITION- KEARL et al., "PD-1/PD-L1 Blockade after Transient Lymphodepletion to Treat Myeloma", Journal of Immunotherapy, (20121100), vol. 35, no. 9, pages 721, 730 - 731, XP055668313
OPPOSITION- "Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy"
OPPOSITION- WEBSTER et al., "Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine", Journal of Immunology, (20070000), vol. 179, pages 2860 - 2869, XP002557388
OPPOSITION- ZENG et al., "Combining anti-PD-1 (B7-H1) immunotherapy with stereotactic radiosurgery in a mouse orthotopic glioblastoma model", Neuro-Oncology, (20111100), vol. 13, pages iii37 - iii38, XP055668314
OPPOSITION- ZENG et al., "Combining anti-PD-1 (B7-H1) immunotherapy with stereotactic radiosurgery in a mouse orthotopic glioblastoma model", International Journal of Radiation Oncology Biology Physics, (20110000), vol. 81, no. 2, pages S82 - S83, XP055064459
OPPOSITION- BRAHMER et al., "Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer", N Engl J Med., (20120000), vol. 366, no. 26, pages 2455 - 2465, XP055668316
OPPOSITION- BRAHMER et al., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", New England Journal of Medicine, (20120000), vol. 366, no. 26, pages 2455 - 2465, XP002685330
OPPOSITION- BRAHMER et al., "Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer", New England Journal of Medicine, (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200694, pages 2455 - 2465, XP002685330
OPPOSITION- BRAHMER et al., "Supplementary Appendix to Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer", New England Journal of Medicine, (2012), vol. 366, page 26pp, XP055668334
OPPOSITION- Brahmer Jr Et Al., "Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer /Supplementary Appendix/", New England Journal of Medicine, (2012), vol. 366, no. 26, pages 2455 - 2465, XP055668334
OPPOSITION- DRAKE, "Combination immunotherapy approaches", Annals of Oncology, (20120000), vol. 23, no. 8, pages viii41 - viii46, XP055679010
OPPOSITION- FORMENTI et al., "Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift", Journal of the National Cancer Institute (JNCI), (20130104), vol. 105, no. 4, doi:10.1093/jnci/djs629, pages 256 - 265, XP055319703
OPPOSITION- DOVEDI et al., "Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade", Cancer Res., (20140000), vol. 74, no. 19, pages 5458 - 5468, XP002743474
OPPOSITION- DOVEDI et al., "Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade", Cancer Research, (20140000), vol. 74, no. 19, pages 5458 - 5468, XP002743474
OPPOSITION- MAKINDE et al., "Radiation Survivors: Understanding and Exploiting the Phenotype following Fractionated Radiation Therapy", NIH Public Access Author Manuscript, (20121121), vol. 11, no. 1, pages 1 - 14, XP055679007
OPPOSITION- STRONCEK et al., "Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting", Journal for ImmunoTherapy of Cancer, (20130000), vol. 1, no. 4, pages 1 - 11, XP021154369
OPPOSITION- KOSINSKY et al., "Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model", Journal for ImmunoTherapy of Cancer, (20180000), vol. 6, no. 17, pages 1 - 15, XP021254324
OPPOSITION- DAVIS et al., "The role of PD-L1 expression as a predictive biomarker an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors", Journal for ImmunoTherapy of Cancer, (20190000), vol. 7, no. 278, pages 1 - 8, XP055679047
OPPOSITION- BURNETTE et al., "The confluence of radiotherapy and immunotherapy", Frontiers in Oncology, (20120000), vol. 2, pages 1 - 8, XP055679002
OPPOSITION- PILON-THOMAS et al., "Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma", J Immunol, (20100301), vol. 184, doi:10.4049/jimmunol.0904114, pages 3442 - 3449, XP002767914
OPPOSITION- PILON-THOMAS et al., "Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma", Journal of Immunology, (20100000), vol. 184, pages 3442 - 3449, XP002767914
OPPOSITION- KEARL et al., "PD-1/PD-L1 Blockade after Transient Lymphodepletion to Treat Myeloma", NIH Public Access Author Manuscript, (20130000), vol. 190, no. 11, pages 1 - 22, XP055678988
OPPOSITION- KEARL et al., "Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion to Treat Myeloma", J Immunol, (20130424), vol. 190, doi:10.4049/jimmunol.1202005, pages 5620 - 5628, XP002770094
OPPOSITION- BASKAR et al., "Cancer and Radiation Therapy: Current Advances and Future Directions", lnternat. Journal of Medical Sciences, (20120000), vol. 9, no. 3, pages 193 - 199, XP055668349
OPPOSITION- BASKAR R. et al., "Cancer and Radiation Therapy: Current Advances and Future Directions", Int J Med Sci, (20120227), vol. 9, no. 3, pages 193 - 199, XP055668349
SEARCH- TENG FEIFEI ET AL, "Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges", CANCER LETTERS, (2015), vol. 365, no. 1, doi:10.1016/J.CANLET.2015.05.012, ISSN 0304-3835, pages 23 - 29, XP029222836 [T] * the whole document *
SEARCH- DAVID KILLOCK, "Immunotherapy: Combined immunoradiotherapy reinvigorates antitumour immunity", NATURE REVIEWS CLINICAL ONCOLOGY, NY, US, (20150324), vol. 12, no. 6, doi:10.1038/nrclinonc.2015.54, ISSN 1759-4774, pages 311 - 311, XP055277370 [T] * abstract *
SEARCH- BAZALOVA MAGDALENA ET AL, "Modality comparison for small animal radiotherapy: A simulation study", MEDICAL PHYSICS, AIP, MELVILLE, NY, US, vol. 41, no. 1, doi:10.1118/1.4842415, ISSN 0094-2405, (20140101), (19010101), XP012184204 [T] * abstract *
SEARCH- WEIQING JING ET AL, "Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, (20150120), vol. 3, no. 1, doi:10.1186/S40425-014-0043-Z, ISSN 2051-1426, page 2, XP021210655 [T] * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents